NVL-520 is under clinical development by Nuvalent and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NVL-520’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NVL-520 overview
NVL-520 is under development for the treatment of ROS1 positive non-small cell lung cancer, other advanced solid tumors and glioblastoma multiforme. It acts by proto oncogene tyrosine protein kinase (ROS1). It is administered through oral route.
Nuvalent overview
Nuvalent is a biopharmaceutical company that discovers and develop novel drug candidates to treat cancer. It investigates its pipeline programs including NVL-520, a novel brain-penetrant ROS1-selective inhibitor; and NVL-655, an ALK-selective inhibitor for the treatment of non-small cell lung cancer (NSCLC). It is also evaluating multiple discovery-stage research programs in the area of oncology. Nuvalent develop small molecules to minimize adverse events and address brain metastases. The company works in collaboration with medical institutions, CROs and CMOs to conduct and support preclinical studies and clinical trials. Nuvalent is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of NVL-520’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
